If data from a third-stage trial is supportive, the company expects to submit an application to the U.S. Food and Drug Administration (FDA) seeking approval for the therapy in the second half of 2026.
The following is a round-up of updates by London-listed companies, issued on Thursday and Friday and not separately reported ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results